ASCO 2023: A phase 1 first-in-human clinical trial of HMBD,Study to Assess Safety and Efficacy of Atezolizumab,Standard Guideline for Investigating and Documenting,TIA ANSI/TIA-222-H-1 VOLUME 2,An Open-label, Multicenter, Phase 1/2 Study to Assess Safety